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THE CD47‑SIGNAL REGULATORY PROTEIN
ALPHA INTERACTION IS A THERAPEUTIC
TARGET FOR HUMAN SOLID TUMORS[7]
Question: Is CD47 a ligand unique to human cancer
cells and not expressed on normal human cells? Can
anti‑CD47 antibody therapy inhibit tumor growth and
prevent or treat tumor metastases?
Human tissue specimens were obtained from various
tumor types including glioblastoma, ovarian, breast,
colon, bladder, hepatocellular carcinoma, and prostate.
CD47 expression was analyzed via flow cytometry. CD47
expression was correlated with survival using Kaplan–
Meier analysis. An in vitro phagocytosis assay was used
to assess the ability of anti‑CD47 antibodies to enable
phagocytosis. In vivo experiments were performed to
assess the ability of anti‑CD47 antibodies to inhibit
tumor growth. Tumors were implanted in their native
location such that glioblastoma cells were implanted
into the left hemisphere of mice. These experiments
were performed in both immune‑deficient and immune
competent mice.
CD47 was highly expressed on nearly all patient tumor
samples evaluated including glioblastoma. Tumor cells
expressed approximately 3.3‑fold more CD47 than
corresponding normal cells. High CD47 expression was

significantly correlated with decreased progression free
and overall survival. In contrast to control experiments,
cells treated with antihuman CD47 antibodies were
efficiently phagocytosed by both mouse and human
macrophages, including glioblastoma neuropsheres. In
the mouse xenografts, glioblastoma growth was inhibited
by anti‑CD47 antibody treatment as compared with
controls. This effect was also seen in the other tumor
models. Using the bladder carcinoma model, metastases
were significantly reduced with anti‑CD47 antibody
treatment as compared with control. Using the breast
cancer model in immune competent hosts, inhibition of
tumor growth was inversely correlated with tumor size.
The antibody treatment was well tolerated with only
self‑limited anemia as a side effect.
CD47 is a nonhousekeeping ligand for signal regulatory
protein alpha (SIRP‑a) that is significantly expressed on a
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wide range of human solid tumors including glioblastoma.
CD47 serves as a “don’t eat me signal” that through
anti‑CD47 antibody treatment results in significant
reduction in tumor growth both in vitro and in vivo.
Perspective: A tumors ability to both grow and
metastasize is reliant on the tumor cells’ ability to
avoid phagocytosis by tumor‑associated macrophages.
This study demonstrates that this “don’t eat me”
signal is reliant on the interaction between CD47 and
SIRP‑a. Interrupting this signal displayed a significant
reduction in tumor growth and ability to metastasize.
Perhaps even more importantly, this treatment was
well tolerated with minimal toxicity. The efficacy of
this treatment appears to be inversely correlated with
tumor size. Consequently, cytoreductive surgery prior
to treatment may be of value. Furthermore, treatment
with additional antitumor antibodies may be of value
in generating a synergistic response. In particular,
antibodies that induce cytotoxicity via their effect on
macrophages, such as cetuximab, may enhance the
ability of anti‑CD47 antibodies to induce phagocytosis.
Based on this research, Phase I/II clinical trials should
be considered using anti‑CD47 antibodies including a
trial for glioblastoma patients.

THREE‑IMENSIONAL MEASUREMENT
GROWTH OF OSSIFICATION OF THE
POSTERIOR LONGITUDINAL LIGAMENT[2]
Question: Ossification of the posterior longitudinal
ligament is a progressive disease, even with surgery.
Is there a better modality to measure radiographic
progression of disease than the use of serial plain X‑rays.
The use of plain radiographs is traditionally used
to monitor bony disease progression with time.
To better understand the volumetric expansion
on bone growth in ossification of the posterior
longitudinal ligament (OPLL), the authors used
serial thin‑slice computed tomography (CT) imaging
to develop 3D models of five patients that were
sequentially followed. Preoperative and sequential
postoperative (laminoplastly) 3D models were
superimposed to allow careful analysis of how (and
equally importantly, where) bone growth progressed
in these five patients. Bony thickness and volume
progression were measured in all patients at mean
follow‑up of 3.1 years (minimum 2 year follow‑up).
Intra‑ and interobserver reproducibility was carefully
measured to validate their results.
Even following operative decompression, bone growth
at the site of the ligament and dorsal vertebral body
continues to progress. The three‑dimensional imaging
system utilizes a voxel‑based, quantitative evaluation of
both the change in bone thickness and volume. They
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found that all five patients had at least 0.5 mm or greater
progression of heterotopic bone. The mean maximal
progression length was 4.7 mm (1.6 mm/year).On
average, patients additionally had a 37% (range 18-89%)
increase in bony volume during the follow‑up period. This
correlated to 484 mm/year. Intraobserver reproducibility
was high: 0.987.
Despite surgery, ossification of the posterior longitudinal
ligament will invariably progress. While previous studies
have shown similar progress, the use of plain X‑rays
limited the radiographic information that could be
obtained. The use of multi‑detector CT imaging may
provide a better 3D understanding of bony progression
and a more precise understanding of both dimensional
and volumetric growth.
Perspective: While it has been previously demonstrated
that bone growth will progress after surgery in OPLL, this
has only been studied with plain X‑rays. This modality
is limited in its ability to evaluate volumetric growth.
Further, it only allows evaluation in craniocaudal and
mediolateral dimensions. Lastly, certain regions of the
cervical spine may be difficult to visualize (especially
the low subaxial cervical spine).The use of the author’s
novel 3D imaging technique allows for a more precise
and useful understanding of disease progression in a
disease that commonly presents many surgical challenges.
Precise 3D information in the postoperative may help
aid both postoperative patient guidance and follow‑up as
well as allows surgeons to make better decisions for their
patients.

SURGICAL TREATMENT OF PATIENTS WITH
VESTIBULAR SCHWANNOMAS AFTER
FAILED PREVIOUS RADIOSURGERY[3]
Question: What is the best treatment option of vestibular
schwannoma patients after failed previous radiosurgery?
The authors reviewed the surgical result of vestibular
schwannoma who underwent surgery during 10 years. The
study cohort was subdivided into group A (radiosurgery
prior to current surgery) and group B (partial removal
followed by radiosurgery prior to current surgery). The
clinical outcomes in the two groups were compared
with those in a patient with control group (no
previous treatment prior to current surgery, matched
characteristics).
There were 15 patients in group A, 13 in group B, and
30 in control group. The authors performed surgery
after radiosurgery due to continuous tumor growth and
progression of neurologic symptoms. They achieved
total tumor removal in all the patients in groups A
and B. (96.7% in control group). There were no
significant differences in the clinical data including
morbidity and complication rate. However, risk of new
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cranial nerve deficits and cerebrospinal fluid (CSF)
leakage was highest in patients in group B. The rate
of anatomical preservation of facial nerve was high in
control group (93.3%, versus 86.7% in group A and 61.5%
in group B). Facial nerve functional preservation was
seen high in control group (87%, versus 78% in group A,
68% in group B).
Complete
microsurgical
removal
of
vestibular
schwannomas after failed radiosurgery is possible with
an acceptable morbidity rate. The functional outcome,
however, tends to be worse than in nontreated patients.
Surgery after previous partial tumor removal and
radiosurgery is most challenging and related to worse
outcome.
Perspective: Treatment of vestibular schwannomas after
previous radiosurgery is challenging. Although surgery could
be considered, the surgical outcomes might not be good due
to previous treatments. Many neurosurgeons are unwilling
to perform surgery to the patients with previous failed
treatment (radiosurgery and/or surgery) due to impact of
tissue trauma (adhesnion between tumor and surrounding
structures, especially brain stem or cranial nerves). This
current study shows acceptable surgical morbidity and
complication rate of patients with failed radiosurgery.
This study, however, is a retrospective study and the study
population is not large enough to generalize their results.
Moreover, this study population’s patients underwent a
surgery by one of the most expert neurosurgeon.

STEREOTACTIC RADIOSURGERY FOR
ARTERIOVENOUS MALFORMATIONS
AFTER EMBOLIZATION: A CASE‑CONTROL
STUDY[4]
Question: The authors sought to determine the efficacy of
treating arteriovenous malformation (AVM) patients with
embolization prior to stereotactic radiosurgery (SRS).
The authors performed a retrospective analysis of
996 patients with AVMs that were treated with SRS
between 1987 and 2006.They identified 120 patients who
were treated with embolization and SRS for their AVMs.
The endpoints used were: Rate of total obliteration,
posttreatment hemorrhages, and permanent neurological
deficits.
The authors reported that the overall rates of complete
AVM obliteration at 3, 4, 5, and 10 years were 35%, 53%,
55%, and 59%, respectively. The rates of hemorrhage for
their patients were 0.8%, 3.5%, 5.4%, 7.7%, and 7.7% at
1, 2, 3, 5, and 10 years, respectively. They also reported a
rate of permanent neurological deficits at 2.5%.
The authors reported that prior embolization
compromised the success of AVM obliteration after
treatment with SRS.
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Perspective: This study provides long‑term follow‑up
on a large number of AVM patients treated with
embolization prior to SRS. The authors found a
statistically significant difference in chances for
obliteration with patients that were treated with
embolization (0 = 0.028). The authors reported that
embolization did not increase the risk for hemorrhage,
but if one were to embolize, then shrinking the AVM to
less than 8 cm3 would improve the rate of obliteration.
While the authors acknowledge the limitations of their
study, their findings suggest that we need to reexamine
our strategies to approaching large AVMs. They suggest
exploring the role of embolization post SRS or to
consider staged treatment of SRS.

IS AGGRESSIVETREATMENT OFTRAUMATIC
BRAIN INJURY COST‑EFFECTIVE?[6]
Question: Is aggressive treatment of severe traumatic
brain injury based on the Brain Trauma Foundation (BTF)
guideline cost‑effective?
The authors used a decision analytical model to evaluate
the outcome and costs of three different management
strategies of traumatic brain injuries (TBI), including
aggressive management (more than 50% of cases are
managed according to the BTF guideline), routine
management (less than 50% are managed according
to the BTF guideline), and comfort care (one day of
intensive care unit (ICU) care followed by care at the
medical‑surgical unit). Clinical outcome and costs
data were extracted from literature reviews, Medicare
reimbursement rate and from a prospective database of
the authors’ group. Quality adjusted life years (QALY)
data was calculated based on GOS data using a
conversion formula and QALYs were estimated for four
age groups (20, 40, 60, and 80 years).
As expected, aggressive care was associated with the
highest acute cost and comfort care was associated with
the lowest acute cost. However, the outcome of patients
with aggressive care was also better, with significantly
more patients achieving independent living and returning
to work, therefore, when factoring in N the long‑term
nursing cost and loss of productivity cost, total life time
cost was actually lower with the aggressive management
strategy for the 20, 40, and 60 year old groups. It was
also more cost effective compared with the other two
strategies. Even for the 80 year old group, the estimated
cost per QALY gained was $88K, which is considered
in some research to be below the threshold of being
considered cost‑effective.
Based on the current model, aggressive treatment
management strategy by following the BTF guideline
is considered as a highly cost effective strategy for the
treatment of traumatic brain injury.
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Perspective: In this study, the authors use a decision
analytical model to estimate the cost effectiveness of
various treatment strategies for severe TBI. Emerging
evidence from literature has shown that intensive therapy
for TBI is associated with better outcome. Although it is
also associated with a higher acute cost, its life time total
cost may actually be lower because of lower long‑term
cost and less loss in productivity. This appears to be
applicable not only to the very young patients, but also
to older patients as well. This study continues to support
an aggressive approach to the treatment of severe TBI,
and suggests that it is not only effective, but also cost
effective.

SIGNIFICANCE OF SIMPSON GRADING
SYSTEM IN MODERN MENINGIOMA
SURGERY: INTEGRATION OF THE GRADE
WITH MIB‑1 LABELING INDEX AS A KEY
TO PREDICT THE RECURRENCE OF WHO
GRADE I MENINGIOMAS[5]
Question: Does the MIB‑1 labeling index provide
additional value in predicting tumor recurrence or
progression in various Simpson grading subsets following
resection of WHO Grade I meningioma?
A retrospective review of 685 patients operated on
for intracranial meningiomas over a 15‑year period
were reviewed. Only patients with World Health
Organization (WHO) Grade I meningiomas were
included in the analysis, with a minimum of 6 months
follow‑up. Patients with neurofibromatosis, prior
radiation or multiple surgeries were excluded from the
analysis.
Two‑hundred and forty patients with 248 WHO
Grade Imeningiomas were included in the analysis.
Extent of resection was correlated with tumor location.
Five‑year recurrence‑free survival (RFS) after Simpson
Grade I, II, III, and IV resections were 97.6%, 87.7%,
84.1%, and 56.8%, respectively. Although a Simpson
Grade of IV correlated significantly with RFS, no
statistically significant correlation was borne out
among Simpson Grades I‑III in predicting RFS.
Only one patient with a Simpson Grade I tumor had
recurrence over the follow‑up period. Among patients
with Simpson Grades II and III, a MIB‑1 labeling
index >3% was significantly correlated with lower
RFS. In addition, a multivariate analysis using a Cox
proportional hazard model for Simpson Grade II and
III resections demonstrated that the MIB‑1 LI was
the single significant predictor of recurrence (Odds
ratio (OR) 4.65, 95% confidence interval (CI) 1.59-14.0;
P = 0.006).
In subtotally resected WHO Grade I meningiomas, the
Simpson Grading System correlates with recurrence in
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Grade IV resections, but may be limited in predicting
recurrence among Grade II and III resections. Routine
incorporation of MIB‑1 labeling index immunostaining,
however, improves the predictive value of recurrence if
the MIB‑1 index is greater than 3% in Simpson Grade II
and III resections.
Perspective: The ability to risk stratify patients with
benign intracranial tumors for recurrence is important,
and as demonstrated by Oya, et al., is contingent on more
than the intraoperative degree of resection in subtotally
resected meningiomas. Tumor progression is associated
with the MIB‑1 labeling index, which can be used to
identify patients who are at higher risk for recurrence,
even among benign WHO Grade I tumors. This lends
support to obtaining routine MIB‑1 immunostaining,
and more recently molecular and genomic profiling, for
subtyping intracranial tumors and improving our ability
to stratify tumor subsets based on behavior and the
propensity for progression.

ADULT GLIOBLASTOMA MULTIFORME
SURVIVAL IN THE TEMOZOLOMIDE ERA:
A POPULATION‑BASED ANALYSIS OF
SURVEILLANCE, EPIDEMIOLOGY, AND END
RESULTS REGISTRIES[1]
Question: Has survival for patients diagnosed
with Glioblastoma (GBM) increased after the use
Temozolomide in the United States?
Data from 19,674 GBM cases, aged 20 years or
greater, diagnosed between 1993 and 2007 in the
populations‑based Surveillance, Epidemiology, and
End Results Program (SEER) database were collected.
Proportional hazards models were used to calculate
calendar period hazard ratios (HR) and 95% CI, adjusted
for demographic covariates. Survival across periods was
compared using the Kaplan–Meier method.
There was a progressive decrease in HRs when comparing
cases diagnosed between 1993 and 1995 to cases diagnosed
between 1999 and 2001.The multivariate‑adjusted HR
for 2005-2007 versus 1993-1995 was 0.69 (95% CI, 0.650.72). Age‑stratified analyses revealed that this progressive
decrease occurred in all age groups except for patients
greater than 80 years of age. Two‑year survival increased
from 7% among cases diagnosed in 19931995 and
19961998 to 9% among cases diagnosed in 1999-2001,
13% in 2002-2004, and 17% in 2005-2007. The disparity
in survival between young and old patients increased in
the temozolomide era, with 2‑year survival of 39% among
cases diagnosed at ages 20-44 years and 1% among cases
diagnosed at 80+ years in 2005-2007.
Using the SEER database, there was a modest but
meaningful population‑based improvement in survival
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of GBM patients. This is likely due to the widespread
use of temozolomide although other advances like
improvements in gross total resection could also play a
role.
Perspectives: It is commonly said that there have been
no advances in the treatment of patients diagnosed
with GBM. This manuscript suggests that the survival
of GBM patients over the past decade since the use of
temozolomide has increased. It is important not only to
evaluate the median overall survival of these patients, but
to look at percent of patients alive at certain time points
as well as looking at certain subclasses of patients. For
example, the survival in patients aged over 80 years has
not significantly improved. In addition, this manuscript
has nice tables, breaking patients into different ages as
well as treatment received and the corresponding median
overall survival and 2 year survival for each of these
groups.
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